Phase 3 Stroke Trial, RecruitingNCT05105633Sponsor: University of MelbourneCondition: Stroke
Printed from Voxsanity (voxsanity.com.au) — NCT05105633 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who are showing symptoms of a stroke affecting the back part of the brain (posterior circulation stroke), caused by a partial or complete blockage of a major artery at the base of the brain called the basilar artery.
Symptoms must have started — or the person must have been last seen well — within the past 24 hours.
The basilar artery blockage must be confirmed by a CT scan or MRI scan of the blood vessels.
People aged 18 years or older.
People who, before this stroke, were either fully independent or needed only minor help at home and could manage on their own for at least one week (a disability score of 3 or less on a standard scale).
Consent requirements under local laws must have been met.
Who may not be able to join:
People whose brain scan shows bleeding in the brain or another condition such as a brain tumour.
People whose brain scan shows a low score on a specific rating system (called pc-ASPECTS) that suggests a large area of the brain has already been seriously damaged (score below 7).
People showing signs of significant swelling in the cerebellum (back of the brain) or a dangerous build-up of fluid on the brain (acute hydrocephalus).
People whose CT scan shows a large area of the brain has already died, suggesting the stroke happened some time ago.
People with extensive damage to both sides of the brainstem.
People where the treating doctor suspects the blockage is due to longstanding narrowing of the arteries or a tear in an artery wall, which may need a different type of procedure rather than clot-dissolving medication.
People who, before this stroke, already had moderate to severe disability (a score of 4 or more on a standard disability scale).
People who have other standard medical reasons why clot-dissolving medication given through a drip would not be safe (confirm with trial site).
People who cannot have contrast dye used during scans.
People who are visibly pregnant.
People who are currently taking part in another research study involving a drug treatment.
People with a known terminal illness where survival beyond one year would not be expected.
People for whom a decision has already been made to withdraw active treatment or move to comfort care only.
People where the treating doctor judges that joining the study could pose a risk to their safety or affect their ability to participate.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Bruce Campbell, University of Melbourne
Bankstown-Lidcombe Hospital, Bankstown, New South Wales
John Hunter Hospital, Newcastle, New South Wales
Liverpool Hospital, Sydney, New South Wales
Gold Coast Hospital, Gold Coast, Queensland
Princess Alexandra Hospital, Woolloongabba, Queensland
Royal Adelaide Hospital, Adelaide, South Australia
Alfred Health, Melbourne, Victoria
Austin Hospital, Melbourne, Victoria
Box Hill Hospital, Melbourne, Victoria
Monash Health, Melbourne, Victoria
Royal Melbourne Hospital, Melbourne, Victoria
+619342 4424
Western Health, Melbourne, Victoria
Fiona Stanley Hospital, Murdoch, Western Australia
Grampians Health, Ballarat,
+61(03) 53305104
Northern Hospital, Melbourne,
+61(03) 8405 8000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT05105633
Sponsor: University of Melbourne
Phase: Phase 3
Status: Recruiting
Condition: Stroke
Trial contact: +6193424424
More information: https://clinicaltrials.gov/study/NCT05105633
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who are showing symptoms of a stroke affecting the back part of the brain (posterior circulation stroke), caused by a partial or complete blockage of a major artery at the base of the brain called the basilar artery.
Symptoms must have started — or the person must have been last seen well — within the past 24 hours.
The basilar artery blockage must be confirmed by a CT scan or MRI scan of the blood vessels.
People aged 18 years or older.
People who, before this stroke, were either fully independent or needed only minor help at home and could manage on their own for at least one week (a disability score of 3 or less on a standard scale).
Consent requirements under local laws must have been met.
Who may not be able to join:
People whose brain scan shows bleeding in the brain or another condition such as a brain tumour.
People whose brain scan shows a low score on a specific rating system (called pc-ASPECTS) that suggests a large area of the brain has already been seriously damaged (score below 7).
People showing signs of significant swelling in the cerebellum (back of the brain) or a dangerous build-up of fluid on the brain (acute hydrocephalus).
People whose CT scan shows a large area of the brain has already died, suggesting the stroke happened some time ago.
People with extensive damage to both sides of the brainstem.
People where the treating doctor suspects the blockage is due to longstanding narrowing of the arteries or a tear in an artery wall, which may need a different type of procedure rather than clot-dissolving medication.
People who, before this stroke, already had moderate to severe disability (a score of 4 or more on a standard disability scale).
People who have other standard medical reasons why clot-dissolving medication given through a drip would not be safe (confirm with trial site).
People who cannot have contrast dye used during scans.
People who are visibly pregnant.
People who are currently taking part in another research study involving a drug treatment.
People with a known terminal illness where survival beyond one year would not be expected.
People for whom a decision has already been made to withdraw active treatment or move to comfort care only.
People where the treating doctor judges that joining the study could pose a risk to their safety or affect their ability to participate.
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 14 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
University of Melbourne
Registry
ClinicalTrials.gov
Start date
29 November 2021
Est. completion
1 May 2028
Where this trial is recruiting
🇦🇺 Australia
🇧🇷 Brazil
🇫🇷 France
15 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Modified Rankin Scale (mRS) 0-1 or return to baseline mRS at 90 days
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.